Multikinase inhibitor decreasing tumor cell proliferation and reducing tumor angiogenesis.

Recommended daily dose is 400 mg (2 × 200 mg tablets) taken twice daily without food.

Indicated for the treatment of advanced renal cell carcinoma and treatment of patients with unresectable hepatocellular carcinoma (HCC).

Dermatologic: hand-foot syndrome, rash

Cardiovascular: hypertension, myocardial infarction

GI: mucositis, dyspepsia, increased lipase, increased amylase, diarrhea, nausea and vomiting, decreased appetite

Increased risk of bleeding

Peripheral neuropathy

Treatment continues until patient no longer benefitting from the therapy or until unacceptable toxicity occurs.

Patients should be cautioned to prevent pregnancy during treatment or for two weeks after treatment. Sorafenib has been shown to cause birth defects or fetal loss.